Optoacoustic technology has been proven in animal and human testing. We have 7 issued patents protecting the technology and its applications and are continuing to build our IP portfolio. The FDA has classified this as a Class II non-significant risk device.
How Optoacoustics Works
- Light pulses into blood in a vessel
- Blood hemoglobin absorbs light & emits ultrasound in proportion to concentration in the vessel
- Ultrasound wave travels without scattering and arrives at specific time proportional to blood vessel depth
- Sensor detects ultrasound
- Software determines location, size, and oxygenation of blood in the vessel
The Optoacoustic Advantage
Other oximeters based on NIRS can only measure a mixture of light from arteries, veins, capillaries, muscle and other absorbing chromophores in a large cone of tissue.
Our optoacoustic technology is better because it provides:
- Direct measurement of cerebral venous oxygenation with high spatial resolution.
- Absolute, accurate measurements of blood oxygenation.
- Continuous, real-time monitoring.
Optoacoustics is a platform technology with several applications in the healthcare market. We estimate the total US market for optoacoustics to be $5.2B ($12.9B worldwide). Of that, pediatrics (neonatal, fetal, cardiac surgery) represents $1.1B (8.5 million measurements). The remaining $4.1B market size is attributable to adult cerebral venous oxygenation (TBI, stroke, cardiac surgery), central venous oxygenation (shock, sepsis, trauma), and hemoglobin concentration monitoring (anemia, blood loss).